MARK SCHOENEBAUM is a Senior Managing Director, Head of ISI’s Health Care Research Team, and is ISI’s Biotechnology & Pharmaceuticals/Major Analyst. Prior to joining ISI, Dr. Schoenebaum was a Managing Director and Senior Biotechnology Analyst at Deutsche Bank. Prior to that, Dr. Schoenebaum held a similar position at Bear Stearns. He has been ranked Institutional Investor #1 Biotechnology analyst for the past 10 consecutive years and has been the #1 Pharmaceuticals analyst for 2 straight years (Mark first initiated on the Pharmaceuticals space 3 years ago). In 2013, Dr. Schoenebaum was inducted into Institutional Investor’s All-America Research Team Hall of Fame, an award given to analysts who have earned at least ten #1 rankings.
Dr. Schoenebaum graduated from Indiana University with highest distinction in 1996 with a BA and received an MD from the Johns Hopkins University School of Medicine in 2000.